RAPP Valuation

Rapport Therapeutics Inc

Add to Watchlist

Advanced Chart

14.770

-0.16(-1.072%)1D

Overview
Forecast
Valuation
Earnings

RAPP Relative Valuation

RAPP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RAPP is overvalued; if below, it's undervalued.

Historical Valuation

Rapport Therapeutics Inc (RAPP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.71. The fair price of Rapport Therapeutics Inc (RAPP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：15.31

Fair

-4.16

Trailing

Forward

-1.80

EV/EBITDA

Rapport Therapeutics Inc. (RAPP) has a current EV/EBITDA of -1.80. The 5-year average EV/EBITDA is -3.12. The thresholds are as follows: Strongly Undervalued below -8.37, Undervalued between -8.37 and -5.74, Fairly Valued between -0.49 and -5.74, Overvalued between -0.49 and 2.13, and Strongly Overvalued above 2.13. The current Forward EV/EBITDA of -1.80 falls within the Historic Trend Line -Fairly Valued range.

-1.64

EV/EBIT

Rapport Therapeutics Inc. (RAPP) has a current EV/EBIT of -1.64. The 5-year average EV/EBIT is -3.25. The thresholds are as follows: Strongly Undervalued below -8.82, Undervalued between -8.82 and -6.03, Fairly Valued between -0.46 and -6.03, Overvalued between -0.46 and 2.32, and Strongly Overvalued above 2.32. The current Forward EV/EBIT of -1.64 falls within the Historic Trend Line -Fairly Valued range.

0.00

Rapport Therapeutics Inc. (RAPP) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-3.96

P/OCF

Rapport Therapeutics Inc. (RAPP) has a current P/OCF of -3.96. The 5-year average P/OCF is -6.72. The thresholds are as follows: Strongly Undervalued below -13.12, Undervalued between -13.12 and -9.92, Fairly Valued between -3.53 and -9.92, Overvalued between -3.53 and -0.33, and Strongly Overvalued above -0.33. The current Forward P/OCF of -3.96 falls within the Historic Trend Line -Fairly Valued range.

-3.84

P/FCF

Rapport Therapeutics Inc. (RAPP) has a current P/FCF of -3.84. The 5-year average P/FCF is 6.08. The thresholds are as follows: Strongly Undervalued below -109.52, Undervalued between -109.52 and -51.72, Fairly Valued between 63.88 and -51.72, Overvalued between 63.88 and 121.68, and Strongly Overvalued above 121.68. The current Forward P/FCF of -3.84 falls within the Historic Trend Line -Fairly Valued range.

Rapport Therapeutics Inc (RAPP) has a current Price-to-Book (P/B) ratio of 1.98. Compared to its 3-year average P/B ratio of 1.71 , the current P/B ratio is approximately 16.01% higher. Relative to its 5-year average P/B ratio of 1.71, the current P/B ratio is about 16.01% higher. Rapport Therapeutics Inc (RAPP) has a Forward Free Cash Flow (FCF) yield of approximately -14.79%. Compared to its 3-year average FCF yield of -11.45%, the current FCF yield is approximately 29.18% lower. Relative to its 5-year average FCF yield of -11.45% , the current FCF yield is about 29.18% lower.

2.07

P/B

Median3y

1.71

Median5y

1.71

-14.70

FCF Yield

Median3y

-11.45

Median5y

-11.45

Competitors Valuation Multiple

The average P/S ratio for RAPP's competitors is 4.03, providing a benchmark for relative valuation. Rapport Therapeutics Inc Corp (RAPP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RAPP.O

Rapport Therapeutics Inc

Palvella Therapeutics Inc

Bicycle Therapeutics PLC

Performance Decomposition

Market capitalization of RAPP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of RAPP in the past 1 year is driven by Unknown.